CASE REPORT
Phaeochromocytoma combined with subclinical Cushing's syndrome and pituitary microadenoma

Guzin Fidan Yaylali, MD1
Fulya Akin, MD1
Mehmet Bastemir, MD1
Yalın Tolga Yaylali2
Akin Ozden, MD3

1Pamukkale University, School of Medicine
Department of Endocrinology and Metabolic Diseases, Denizli, Turkey
2Servergazi State Hospital Department of Cardiology, Denizli, Turkey
3Pamukkale University, School of Medicine
Department of Surgery, Denizli, Turkey

Manuscript submitted 8th February, 2008
Manuscript accepted 28th April, 2008


Abstract

Objectives: Phaeochromocytoma (PHEO) occasionally associates with pathological lesions of the adrenal cortex. The coexistence of PHEO and pre-clinical Cushing's syndrome (PCS) of the same adrenal gland has rarely been reported. We report a case of PHEO and PCS originating from the same adrenal gland and discuss the peculiar diagnostic aspects of this entity.

Clinical Presentation: A 64 yr old man was hospitalized to evaluate the right adrenal mass which was discovered incidentally by ultrasonography. He had a history of type 2 diabetes mellitus and hyperlipidemia. Blood pressure measurements were all normal during his hospital stay. Laboratory examination showed: urinary catecholamines were markedly increased. HbA1C of 14.3 %, midnight cortisol of 11(μg/dL), cortisol was not suppressed after the overnight 1 mg oral dexamethasone suppression test (DST): 3.42(μg/dL), 24 hr free cortisol in the urine : 213 μg/day (10-100), cortisol levels were suppressed more than 50% with 8 mg of dexamethasone. CT scan of the adrenal glands showed a 6 cm well encapsulated right adrenal mass together with a clearly normal left adrenal gland. MRI investigation of the sella turcica revealed a pituitary microadenoma on the right side of the adenohypophysis. He was treated with α and subsequent β blockers after the diagnosis of PHEO and PCS was made. Right adrenalectomy was performed. The pathology showed typical PHEO with adrenocortical hyperplasia. VMA, metanephrin and free cortisol levels were normalized one month after surgery.

Conclusion: The present report is a rare case of PHEO combined with PCS in the same adrenal gland.

Hypercortisolism in patients with tumours of the autonomic nervous system has been reported previously. Luton et al. reviewed cases with pheochromocytoma and hypercortisolism due to adrenal tumours.1 Other combinations include the production of steroid hormones by a tumour of the autonomic nervous system, concomitant adreno-cortical and -medullary tumours, ectopic production of corticotropin releasing factor (CRF), and multiple endocrine neoplasia.2,3 In most of cases of phaeochromocytoma (PHEO) associated with Cushing’s syndrome (CS), ectopic adrenocorticotropic hormone (ACTH) produced by PHEO resulted in bilateral adrenocortical hyperplasia.4,5 Co-existence of PHEO and non-ACTH dependent CS is very rare.6,7
Cortisol secreting cortical adenomas present clinically as CS, but may also be silent, exhibiting only lack of dexamethazone suppression and occasionally increased urinary cortisol excretion, the so-called preclinical or subclinical CS (PCS). The prevalence of PCS discovered from adrenal incidentalomas has varied from 6-20%, because of various diagnostic criteria and the small number of cases to be examined statistically.

We report a case of PHEO and PCS originating from the same adrenal gland which is extremely rare.

**Clinical Presentation**

A 64 yr old man was hospitalized to evaluate the right adrenal mass which was incidentally discovered by abdominal ultrasonography. He was 170 cm tall, 72 kg weight, and 25 kg/m² body mass index. He had a history of type 2 diabetes mellitus and hyperlipidemia. He complained of occasional sweating and weight loss of 10 kg over the last 5 months. He was taking repaglinide 3 mg tid and metformin 850 mg bid prior to admission. Treatment was switched to intensive insulin treatment due to his HbA1C of 14.3%. His c-peptide level was 1.77 and fasting insulin 26.5 at that time showing insulin resistance. Blood sugar concentration was controlled with 150 units of insulin per day.

Physical examination was unremarkable on admission. Blood pressure measurements during hospital stay and blood pressure Holter monitoring were all normal. Laboratory results shown in Table 1. Cardiac work up was normal including normal echocardiography and negative exercise stress test. There was no diabetic retinopathy.

CT scan of the adrenal glands showed a 6 cm well encapsulated right adrenal mass together with a clearly normal left adrenal gland (figure 1). MRI investigation of the sella turcica revealed a pituitary microadenoma (4 mm in diameter) on the right side of the adenohypophysis (figure 2).

He was treated with α and subsequent β blockers after the diagnosis of PHEO and PCS was made. After 1 week of α blocker (doxazosin 4 mg bid) therapy he received 2 weeks of β blocker (carvedilol 12.5 mg bid) before surgery (figure 3). He received 2000 ml

<table>
<thead>
<tr>
<th>TABLE 1. Baseline laboratory parameters.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biochemical parameters (plasma)</strong></td>
</tr>
<tr>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>Fasting blood glucose (mg/dL)</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
</tr>
<tr>
<td>LDL Cholesterol (mg/dL)</td>
</tr>
<tr>
<td>AST (IU/L)</td>
</tr>
<tr>
<td>ALT (IU/L)</td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
</tr>
<tr>
<td>Na (mmol/L)</td>
</tr>
<tr>
<td>K (mmol/L)</td>
</tr>
<tr>
<td>Calcium (mmol/L)</td>
</tr>
<tr>
<td>Phosphorus (mmol/L)</td>
</tr>
</tbody>
</table>

**ACTH:** adrenocorticotropic hormone  
**AST:** aspartate aminotransferase  
**ALT:** alanine aminotransferase  
**BUN:** blood urea nitrogen  
**DHEA-S:** dehydroepiandrosterone sulphate  
**FSH:** follicle stimulating hormone  
**Ft4:** free thyroxine  
**IGF-1:** insulin like growth factor  
**LH:** luteinizing hormone  
**PTH:** parathyroid hormone  
**TSH:** thyroid stimulating hormone
saline infusion per day for one week preoperatively. We looked for other MEN2a components before the surgery but neither of them existed. Osteomalacia was diagnosed, based on normal calcium levels, PTH at the upper limit of normal and very low vitamin D levels and he was given vit D. As he had PCS, methylprednisolone (40 mg per day) was commenced on the day before surgery and tapered off gradually over 2 weeks. He also received intensive insulin treatment of 200 IU/ day. The pathology showed typical PHEO with positive immunostaining for chromogranine A, synapthophysin and adrenocortical hyperplasia. There was no information about ACTH immunohistochemistry in tumour tissue. There were no hypotensive/hypertensive and/or hypoglycemia attacks during or after surgery.

Insulin was tapered and he was discharged on metformin 1000 mg bid, rosiglitazone 4 mg bid one month postoperatively and he had no hypertensive attacks. Two months after surgery his fasting blood glucose was 116 mg/ dl and his HbA1c was 6.2. (Table 2) The MRI studies of his pituitary and adrenal glands were completely normal 3 months later.

Discussion

An explanation for the occurrence of CS in some patients with PHEO was provided by the observation that PHEO can secrete an ACTH like polypeptide which induces bilateral adrenocortical hyperplasia and hyperfunction, thus causing “ectopic ACTH syndrome”.9 PHEO and CS may sometimes coexist and, very rarely, originate from the same adrenal gland. There have been 12 cases in the literature, in which corticomедullary involvement has been reported.6,7 In our case, PHEO and cortical hyperplasia coexisted in the same adrenal gland. The patient...
was asymptomatic as far as PHEO or CS, in contrast to the 12 cases in the literature, most of which had symptoms related to either PHEO or CS. In addition, our case had normal blood pressure throughout. Up to 13% of the patients present with persistently normal blood pressure due to the catecolamine secretion; receptor down regulation because of consistently high levels of catecolamines; hypovolemia; and associated changes in sympathetic nerve function. Most phaeochromocytomas produce excess norepinephrine causing hypertension, some produce epinephrine causing hypotension, and about 13% produce both, the balance of which determines the blood pressure. Insulin requirement was almost 200 IU per day preoperatively. One week after surgery blood sugar was controlled with metformin and rosiglitazone. This suggests that metabolic disorders with insulin resistance should be kept in mind, even if there is no clinical evidence, in patients who need large doses of insulin for blood glucose control.

In our patient, a high-dose 8-mg DEX suppression test using 24-hour urine cortisol showed more than 50% suppression, indicating a pituitary cause of CS with 90% sensitivity and 79% specificity, MRI investigation of the sella turcica revealed a pituitary microadenoma (4mm in diameter) on the right side of the adenohypophysis. Since the high-dose 8-mg DEX suppression test did not show more than 90% suppression, it indicates either a primary adrenal or ectopic ACTH cause of CS. Alternatively, this suggests the possibility of a pituitary cause with more sensitivity and specificity, if it showed more than 90% suppression. There was no bilateral adrenal hyperplasia on imaging which raises the possibility of the pituitary as a cause of CS. Thus, the 8 mg dex suppression test would have pointed out the possibility of the pituitary cause. The absence of bilateral adrenal hyperplasia on

<table>
<thead>
<tr>
<th>Biochemical parameters (plasma)</th>
<th>Hormone levels (normal values)</th>
<th>1 mg dex suppression (μg/dL)</th>
<th>24 hour free cortisol in the urine (mcg/d)</th>
<th>VMA (mg/d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting blood glucose (mg/dL)</td>
<td>116 DHEA-S (μg/dL) 33 (35-430)</td>
<td>1.62</td>
<td>28 (10-100)</td>
<td>73.1 (52-341)</td>
</tr>
<tr>
<td>Total cholesterol(mg/dL)</td>
<td>197 ACTH (pg/ml) 63 (0-46)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
<td>231 Cortisol (μg/dL) 18.9 (5-25)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL Cholesterol(mg/dL)</td>
<td>116 FSH (mIU/mL) 4.63 (1.5-12.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST (IU/L)</td>
<td>18 LH (mIU/mL) 4.21 (1.7-8.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT (IU/L)</td>
<td>23 Testosterone (ng/dl) 341 (181-758)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>17 IGF-1 (ng/mL) 58.9 (71-290)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.7 TSH mIU/mL 1.35 (0.7-4.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTH (pg/mL)</td>
<td>133 Ft4 (ng/dl) 1.27</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vit D (ng/mL)</td>
<td>&lt;7 HbA1C 6.2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACTH: adrenocorticotropic hormone
AST: aspartate aminotransferase
ALT: alanine aminotransferase
BUN: blood urea nitrogen
DHEA-S: dehydroepiandrosterone sulphate
FSH: follicle stimulating hormone
Ft4: free thyroxine
IGF-1: insulin like growth factor
LH :luteinizing hormone
PTH: parathyroid hormone
TSH: thyroid stimulating hormone
imaging ruled out CD or ectopic ACTH. One month after right adrenalectomy cortisol metabolism was normal and, therefore, we considered that the hypophyseal adenoma was incidental. If the cause had been pituitary from the outset, cortisol metabolism would not be normalized month after adrenalectomy. Also, MRI study of the pituitary gland seven months after the operation was normal. This suggests that the preoperative MRI report was over-read.

Autonomous glucocorticoid production without specific signs and symptoms of Cushing's syndrome is termed preclinical Cushing's syndrome. With an estimated prevalence of 79 cases per 100,000 persons, subclinical Cushing's syndrome is much more common than classic Cushing's syndrome. Patients with subclinical Cushing's syndrome lack the classical stigmata of hypercortisolism but have a high prevalence of obesity, hypertension, and type 2 diabetes. PCS exhibits only lack of dexamethasone suppression and occasionally increased urinary cortisol excretion. Morioka et al reported seven Japanese cases of PCS and observed that the most frequently found biochemical parameters of autonomous cortisol secretion were a low adrenocorticotropic hormone (ACTH) level (100%) and insufficient suppression of cortisol by low-dose dexamethasone (85.7%).

Our case fulfilled the two required criteria, incidental adrenal mass associated with autonomous cortisol overproduction and lack of clinical characteristics of CS. We therefore diagnosed this case as PCS.

A critical issue is whether preclinical Cushing’s syndrome may predispose to diseases such as arterial hypertension, obesity, or diabetes that are classical features of endogenous hypercortisolism and cluster in the metabolic syndrome. This is biologically plausible since many patients with clinically inapparent adrenal adenoma can be exposed to a chronic, albeit slight, cortisol excess. There are data indicating that some patients with subtle glucocorticoid excess may develop metabolic derangements, including insulin resistance, that may predispose to atherosclerosis and relevant cardiovascular complications. Interestingly, alterations in glucose metabolism and reduced insulin sensitivity are not restricted to patients with preclinical Cushing's syndrome. However, they are more marked in such patients than in those harboring non-functioning adenoma. An alternative hypothesis that adrenal incidentaloma may itself be an unrecognized manifestation of the metabolic syndrome could not be ruled out. A causal link between preclinical Cushing’s syndrome and insulin resistance is the most plausible explanation for the available data.

**Conclusion**

PHEO and cortical hyperplasia rarely coexist in the same adrenal gland. Cases in the literature had clinical features of either PHEO or CS. In our patient, we found an adrenal mass incidentally and the case is a rare report of PHEO combined with PCS in the same adrenal gland. It is important to investigate cortisol metabolism in patients with PHEO to diagnose concurrent clinical/subclinical CS. In the differential diagnosis of Cushing Syndrome, laboratory data and imaging studies might not always point towards a correct diagnosis. It is important to keep in mind that false positive results of tests and studies may complicate the clinical presentation.

**References**


Correspondence to:

Guzin Fidan Yaylali, MD
Pamukkale University, School of Medicine
Department of Endocrinology and Metabolic Diseases
Kınıklı Campusu 20070 Kınıklı, Denizli, Turkey
E-mail: guzinf@gmail.com